On August 22, 2024 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that CFO Raphi Levy will present a corporate overview and update at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th, 2024 and in the Sidoti Virtual Investor Conference on September 18-19th, 2024 and will participate in the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference on September 26th, 2024 and the Lytham Partners Fall 2024 Investor Conference on October 1st, 2024 (Press release, Alpha Tau Medical, AUG 22, 2024, View Source [SID1234646050]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: September 10, 2024
Time: 12:00 – 12:30PM EST
Location: New York, NY

Event: Sidoti Small-Cap Virtual Investor Conference
Date: September 19, 2024
Time: 11:30AM – 12:00PM EST
Location: Virtual

Event: Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference
Date: September 26, 2024
Time: 8:30AM – 2:30PM EST
Location: New York, NY

Event: Lytham Partners Fall 2024 Investor Conference
Date: October 1, 2024
Time: 8:00AM – 7:00PM EST
Location: Virtual

Mr. Levy will be available for 1×1 investor meetings at all conferences. Please reach out to your H.C. Wainwright, Sidoti, Rothschild & Co, or Lytham Partners representatives to schedule.

On August 22, 2024 Vir Biotechnology Inc. (NASDAQ: VIR) reported that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City (Press release, Vir Biotechnology, AUG 22, 2024, View Source [SID1234646066]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

On August 22, 2024 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported that members of the Company’s senior management team will participate in the following investor conferences in September 2024 (Press release, Zai Laboratory, AUG 22, 2024, View Source [SID1234646067]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference
Location: New York, New York

Cantor Fitzgerald Global Healthcare Conference
Fireside Chat: Thursday, September 19, 2024, 8:00 a.m. ET in Track 2
Location: New York, New York

On August 22, 2024 Aveta Biomics, a pioneering oncology company developing first-in-class oral immuno-oncology drugs, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to APG-157, its next-generation immuno-oncology drug, for the neoadjuvant treatment of Head and Neck Cancer (HNC) (Press release, Aveta Biomics, AUG 22, 2024, View Source [SID1234646052]). This designation underscores the potential of APG- 157 to address a significant unmet medical need in treating a highly challenging form of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The FDA’s Fast Track Designation is intended to facilitate the development and to expedite the review of drugs aimed at treating serious conditions with unmet medical needs. This designation allows for more frequent interactions with the FDA, eligibility for rolling submissions for a marketing application, and potential Accelerated Approval, ultimately aiming to bring promising new treatments to patients more rapidly.

"There is an urgent need for new treatments for head and neck cancer patients, many of whom face poor survival odds and considerable morbidities following current standard-of-care treatments, including surgery, radiotherapy, and chemotherapy/targeted treatments. The rare grant of Fast Track Designation for neoadjuvant treatment in Head and Neck Cancer underscores the FDA’s recognition of the potential role of APG-157 in providing meaningful treatment benefits to these patients," said Parag Mehta, PhD, Chief Executive Officer of Aveta Biomics.

Head and Neck Cancer affects approximately 900,000 people globally, with an overall five-year mortality rate of around 50%, a figure that has remained largely unchanged for decades. The molecular complexity of these tumors presents significant challenges for existing treatments, including targeted therapies. APG-157 is a first-in-class drug that acts through a dual mechanism: inducing selective apoptosis of cancer cells while also reprogramming the immune environment.

"This Fast Track Designation, based on our comprehensive Phase 1 and Phase 2 data, accelerates our ability to bring our promising first-line therapy to all newly diagnosed, locally advanced Head and Neck Cancer patients in a frontline setting," added Karim Malek, MD, MTh, MBA, Chief Medical Officer of Aveta Biomics.

On August 22, 2024 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company plans to present at the following conferences (Press release, BioCryst Pharmaceuticals, AUG 22, 2024, View Source [SID1234646053]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 p.m. ET.
H.C. Wainwright 26th Annual Global Investment Conference in New York on Monday, September 9, 2024, at 9:00 a.m. ET.
2024 Cantor Global Healthcare Conference in New York on Thursday, September 19, 2024, at 12:45 p.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.